These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33257497)

  • 1. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.
    Khanna D; Huang S; Lin CJF; Spino C
    Ann Rheum Dis; 2021 May; 80(5):641-650. PubMed ID: 33257497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
    Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE
    Arthritis Rheumatol; 2016 Feb; 68(2):299-311. PubMed ID: 26808827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
    Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE
    Arthritis Care Res (Hoboken); 2016 Feb; 68(2):167-78. PubMed ID: 26806474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Khanna D; Spino C; Johnson S; Chung L; Whitfield ML; Denton CP; Berrocal V; Franks J; Mehta B; Molitor J; Steen VD; Lafyatis R; Simms RW; Gill A; Kafaja S; Frech TM; Hsu V; Domsic RT; Pope JE; Gordon JK; Mayes MD; Schiopu E; Young A; Sandorfi N; Park J; Hant FN; Bernstein EJ; Chatterjee S; Castelino FV; Ajam A; Wang Y; Wood T; Allanore Y; Matucci-Cerinic M; Distler O; Singer O; Bush E; Fox DA; Furst DE
    Arthritis Rheumatol; 2020 Jan; 72(1):125-136. PubMed ID: 31342624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.
    Arnold MB; Khanna D; Denton CP; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE; Pope JE
    Rheumatology (Oxford); 2018 Jan; 57(1):152-157. PubMed ID: 29077900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS).
    Zheng B; Hudson M; Wang M; Baron M;
    Arthritis Res Ther; 2020 Jun; 22(1):132. PubMed ID: 32503616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP;
    Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
    Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
    Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
    Spiera R; Kuwana M; Khanna D; Hummers L; Frech TM; Stevens W; Matucci-Cerinic M; Kafaja S; Distler O; Jun JB; Levy Y; Leszcyzński P; Gordon J; Steen V; Lee EB; Jankowski T; Litinsky I; Chung L; Hsu V; Mayes M; Sandorfi N; Simms RW; Finzel S; de Vries-Bouwstra J; Constantine S; Dgetluck N; Dinh Q; Bloom BJ; Furst DE; White B; Denton CP;
    Arthritis Rheumatol; 2023 Sep; 75(9):1608-1618. PubMed ID: 37098795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.
    Spiera R; Hummers L; Chung L; Frech TM; Domsic R; Hsu V; Furst DE; Gordon J; Mayes M; Simms R; Lafyatis R; Martyanov V; Wood T; Whitfield ML; Constantine S; Lee E; Dgetluck N; White B
    Arthritis Rheumatol; 2020 Aug; 72(8):1350-1360. PubMed ID: 32336038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
    Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
    Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.
    Pincus T; Amara I; Koch GG
    Arthritis Rheum; 2005 Apr; 52(4):1031-6. PubMed ID: 15818698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.
    Spiera R; Khanna D; Kuwana M; Furst DE; Frech TM; Hummers L; Stevens W; Matucci-Cerinic M; Baron M; Distler O; Dgetluck N; Bloom BJ; Dinh Q; White B; Denton CP
    Clin Exp Rheumatol; 2021; 39 Suppl 131(4):124-133. PubMed ID: 34323681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.
    Zheng B; Wang M; Stevens W; Proudman S; Nikpour M; Baron M; ;
    Semin Arthritis Rheum; 2022 Apr; 53():151973. PubMed ID: 35149318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
    Khanna D; Yan X; Tashkin DP; Furst DE; Elashoff R; Roth MD; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M; Clements PJ;
    Arthritis Rheum; 2007 May; 56(5):1676-84. PubMed ID: 17469162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
    Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.
    Valentini G; Paone C; La Montagna G; Chiarolanza I; Menegozzo M; Colutta E; Ruocco L
    Scand J Rheumatol; 2006; 35(1):35-8. PubMed ID: 16467039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
    Domsic RT; Medsger TA; Gao S; Laffoon M; Huang S; Wisniewski S; Spino C; Steen V; Lafyatis R; Khanna D
    Rheumatology (Oxford); 2023 Apr; 62(4):1543-1551. PubMed ID: 36031807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.
    Khanna D; Furst DE; Hays RD; Park GS; Wong WK; Seibold JR; Mayes MD; White B; Wigley FF; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally EV; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
    Ann Rheum Dis; 2006 Oct; 65(10):1325-9. PubMed ID: 16540546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.